Bruker Corporation (BRKR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BRKR SEC filings page.
Bruker Corporation (BRKR) reported $3.5B in revenue over the twelve months to Jun 30, 2026, up 1.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue barely grew in FY2025, while margin compression and heavier operating costs pushed a once-profitable model near break-even.
The clearest earnings-quality split is in FY2025: the company reported a net loss of$8.3M but still generated operating cash flow of$134M , indicating cash generation was supported by noncash charges rather than accounting profitability. Depreciation and amortization was$220M while free cash flow was only$43.3M , so positive operating cash did not translate into much cash after reinvestment.
Revenue increased
The asset base expanded to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bruker Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bruker Corporation has an operating margin of 2.0%, meaning the company retains $2 of operating profit per $100 of revenue. This results in a moderate score of 54/100, indicating healthy but not exceptional operating efficiency. This is down from 7.5% the prior year.
Bruker Corporation's revenue grew a modest 2.1% year-over-year to $3.4B. This slow but positive growth earns a score of 59/100.
Bruker Corporation has elevated debt relative to equity (D/E of 0.75), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 11/100, reflecting increased financial risk.
Bruker Corporation's current ratio of 1.73 indicates adequate short-term liquidity, earning a score of 51/100. The company can meet its near-term obligations, though with limited headroom.
Bruker Corporation has a free cash flow margin of 1.3%, earning a moderate score of 38/100. The company generates positive cash flow after capital investments, but with room for improvement.
Bruker Corporation posts a -0.3% return on equity (ROE), meaning it loses less than $1 for every $100 of shareholders' equity. This results in a returns score of 50/100. This is down from 6.4% the prior year.
Bruker Corporation scores 2.74, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($9.0B) relative to total liabilities ($3.7B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bruker Corporation passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Bruker Corporation reported a net loss of $8.3M while generating $134.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Bruker Corporation earns $1.13 in operating income for every $1 of interest expense ($68.2M vs $60.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Bruker Corporation generated $838.5M in revenue in Q2 2026. This represents an increase of 5.2% from the same quarter a year earlier. Against the prior quarter it is up 1.8%.
Bruker Corporation's EBITDA was -$7.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 110.7% from the same quarter a year earlier. Against the prior quarter it is down 110.7%.
Bruker Corporation reported -$52.0M in net income in Q2 2026. This represents a decrease of 784.2% from the same quarter a year earlier. Against the prior quarter it is down 461.1%.
Bruker Corporation earned -$0.41 per diluted share (EPS) in Q2 2026. This represents a decrease of 920.0% from the same quarter a year earlier.
Cash & Balance Sheet
Bruker Corporation recorded an outflow of $106.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 28.6% from the same quarter a year earlier. Against the prior quarter it is down 326.0%.
Bruker Corporation held $184.9M in cash against $1.8B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Bruker Corporation's gross margin was 49.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 4.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.
Bruker Corporation's operating margin was -7.8% in Q2 2026, reflecting core business profitability. This is down 9.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.0 percentage points.
Bruker Corporation's net profit margin was -6.2% in Q2 2026, showing the share of revenue converted to profit. This is down 7.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.0 percentage points.
Bruker Corporation's ROE was -2.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.8 percentage points.
Capital Allocation
Bruker Corporation invested $94.3M in research and development in Q2 2026. This represents a decrease of 5.9% from the same quarter a year earlier. Against the prior quarter it is down 6.9%.
Bruker Corporation invested $28.8M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 35.2% from the same quarter a year earlier. Against the prior quarter it is up 19.0%.
Not reported for Q2 2026.
BRKR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $838.5M+5.2% | $823.4M+2.7% | $977.2M-0.2% | $860.5M-0.5% | $797.4M-0.4% | $801.4M+11.0% | $979.6M+14.6% | $864.4M+16.4% |
| Cost of Revenue | $422.5M-3.9% | $443.6M+8.1% | $528.0M+8.6% | $481.1M+8.0% | $439.5M+5.6% | $410.2M+11.2% | $486.3M+14.6% | $445.6M+23.8% |
| Gross Profit | $416.0M+16.2% | $379.8M-2.9% | $449.2M-8.9% | $379.4M-9.4% | $357.9M-6.9% | $391.2M+10.9% | $493.3M+14.6% | $418.8M+9.4% |
| R&D Expenses | $94.3M-5.9% | $101.3M+4.3% | $99.6M-4.6% | $98.3M+0.2% | $100.2M+8.7% | $97.1M+18.7% | $104.4M+25.0% | $98.1M+37.6% |
| SG&A Expenses | $238.9M+3.2% | $242.1M+7.4% | $247.2M0.0% | $242.5M+5.5% | $231.4M+4.6% | $225.4M+15.4% | $247.3M+17.1% | $229.9M+29.4% |
| Operating Income | -$65.3M-648.7% | $10.2M-67.9% | $76.3M+5.8% | -$51.8M-176.1% | $11.9M-75.3% | $31.8M-50.9% | $72.1M-30.3% | $68.1M-45.3% |
| EBITDA | -$7.3M-110.7% | $68.5M-16.7% | $134.4M+7.4% | $3.9M-96.7% | $68.0M-27.0% | $82.2M-17.4% | $125.1M-11.2% | $119.1M-21.2% |
| Interest Expense | $17.8M+13.4% | $12.2M-6.9% | $11.2M-28.2% | $20.3M+75.0% | $15.7M0.0% | $13.1M+162.0% | $15.6M+254.5% | $11.6M+197.4% |
| Income Tax | $14.2M+558.1% | $2.5M-71.3% | $37.8M-7.1% | -$14.1M-195.3% | -$3.1M-119.3% | $8.7M-56.1% | $40.7M+9.7% | $14.8M-51.9% |
| Net Income | -$52.0M-784.2% | $14.4M-17.2% | $26.3M+82.6% | -$59.6M-245.7% | $7.6M0.0% | $17.4M-65.8% | $14.4M-93.0% | $40.9M-53.6% |
| EPS (Basic) | -$0.41-920.0% | $0.02-81.8% | $0.10+11.1% | -$0.41-251.9% | $0.050.0% | $0.11-68.6% | $0.09-93.6% | $0.27-55.0% |
| EPS (Diluted) | -$0.41-920.0% | $0.02 | $0.10 | -$0.41-251.9% | $0.050.0% | $0.11-68.6% | $0.09-93.6% | $0.27-55.0% |
| Diluted Shares (Avg) | 152M+0.4% | 153M | N/A | 152M-0.1% | 152M+2.5% | 152M+104040995.9% | N/A | 152M+103401260.5% |
BRKR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.1B-4.5% | $6.1B+3.3% | $6.2B+7.5% | $6.4B+5.3% | $6.3B+7.4% | $5.9B+31.7% | $5.8B+36.6% | $6.1B+60.0% |
| Current Assets | $2.2B+2.9% | $2.1B-0.4% | $2.2B+7.8% | $2.4B+7.3% | $2.2B+0.5% | $2.1B-1.4% | $2.1B-5.1% | $2.2B+8.0% |
| Cash & Equivalents | $184.9M+101.0% | $133.4M-27.6% | $298.8M+62.9% | $293.1M+97.9% | $92.0M-45.8% | $184.2M-45.8% | $183.4M-62.4% | $148.1M-59.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $1.1B-8.1% | $1.1B+0.4% | $1.1B+2.5% | $1.2B-2.0% | $1.2B+3.6% | $1.1B+5.3% | $1.1B+10.3% | $1.2B+33.2% |
| Accounts Receivable | $545.9M+4.5% | $542.7M+0.9% | $544.9M-3.6% | $550.9M+2.3% | $522.6M+3.0% | $537.8M+13.1% | $565.5M+14.9% | $538.4M+10.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.4B-13.3% | $1.6B+2.6% | $1.5B+2.7% | $1.5B+5.1% | $1.6B+14.2% | $1.5B+103.9% | $1.5B+158.7% | $1.5B+96.1% |
| Total Liabilities | $3.7B-19.2% | $3.7B-10.6% | $3.7B-6.5% | $4.0B-6.2% | $4.5B+10.8% | $4.1B+34.2% | $4.0B+40.7% | $4.3B+63.5% |
| Current Liabilities | $1.2B-10.6% | $1.4B+0.8% | $1.3B-0.2% | $1.3B-4.1% | $1.3B+3.3% | $1.3B+13.7% | $1.3B+6.6% | $1.3B+23.3% |
| Non-Current Liabilities | $2.4B-22.8% | $2.3B-16.2% | $2.5B-9.5% | $2.7B-7.2% | $3.2B+14.4% | $2.8B+47.1% | $2.7B+65.8% | $2.9B+91.6% |
| Long-Term Debt | $1.8B-23.7% | $1.7B-19.9% | $1.9B-10.2% | $2.0B-12.4% | $2.4B+11.6% | $2.1B+53.0% | $2.1B+77.7% | $2.3B+106.1% |
| Total Equity | $2.4B+31.9% | $2.5B+34.6% | $2.5B+37.9% | $2.4B+34.6% | $1.8B+1.7% | $1.8B+29.5% | $1.8B+29.3% | $1.8B+49.5% |
| Retained Earnings | N/A | N/A | $2.4B-1.9% | $2.4B-2.0% | N/A | N/A | $2.4B+3.6% | $2.4B |
BRKR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$77.4M+39.3% | $71.2M+9.5% | $229.8M+20.9% | -$33.2M-186.5% | -$127.5M-11690.9% | $65.0M+198.2% | $190.0M-7.5% | $38.4M-12.9% |
| Depreciation & Amortization | $58.0M+3.4% | $58.3M+15.7% | $58.1M+9.8% | $55.7M+9.2% | $56.1M+24.4% | $50.4M+45.2% | $52.9M+41.8% | $51.0M+91.7% |
| Stock-Based Compensation | $5.6M-1.8% | $6.0M+7.1% | N/A | $6.0M+5.3% | $5.7M+11.8% | $5.6M+5.7% | N/A | $5.7M+18.8% |
| Capital Expenditures | $28.8M+35.2% | $24.2M-6.9% | $22.6M-38.4% | $20.9M-35.9% | $21.3M-13.4% | $26.0M+21.5% | $36.7M+16.5% | $32.6M+21.2% |
| Free Cash Flow | -$106.2M+28.6% | $47.0M+20.5% | $207.2M+35.2% | -$54.1M-1032.8% | -$148.8M-533.2% | $39.0M+9650.0% | $153.3M-11.9% | $5.8M-66.3% |
| Investing Cash Flow | -$25.3M+72.2% | -$39.7M-52.1% | -$55.5M+8.4% | -$23.8M+64.8% | -$91.1M+93.1% | -$26.1M+91.4% | -$60.6M-64.7% | -$67.6M+56.4% |
| Financing Cash Flow | $149.2M+56.2% | -$204.9M-300.2% | -$167.6M-123.5% | $258.4M+9670.4% | $95.5M-91.7% | -$51.2M-133.8% | -$75.0M-25.2% | -$2.7M+97.1% |
| Dividends Paid | $7.5M-1.3% | $7.6M-1.3% | $7.5M-1.3% | $0-100.0% | $7.6M-1.3% | $7.7M+5.5% | $7.6M+4.1% | $7.6M+2.7% |
| Share Buybacks | N/A | $0-100.0% | $0 | $0 | $0 | $10.0M | $0-100.0% | $0-100.0% |
BRKR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.6%+4.7pp | 46.1%-2.7pp | 46.0%-4.4pp | 44.1%-4.4pp | 44.9%-3.2pp | 48.8%-0.1pp | 50.4%0.0pp | 48.4%-3.1pp |
| Operating Margin | -7.8%-9.3pp | 1.2%-2.7pp | 7.8%+0.5pp | -6.0%-13.9pp | 1.5%-4.5pp | 4.0%-5.0pp | 7.4%-4.8pp | 7.9%-8.9pp |
| Net Margin | -6.2%-7.1pp | 1.8%-0.4pp | 2.7%+1.2pp | -6.9%-11.7pp | 0.9%0.0pp | 2.2%-4.9pp | 1.5%-22.7pp | 4.7%-7.1pp |
| Return on Equity | -2.2%-2.6pp | 0.6%-0.4pp | 1.1%+0.3pp | -2.5%-4.7pp | 0.4%0.0pp | 0.9%-2.6pp | 0.8%-14.2pp | 2.3%-5.0pp |
| Return on Assets | -0.9%-1.0pp | 0.2%-0.1pp | 0.4%+0.2pp | -0.9%-1.6pp | 0.1%0.0pp | 0.3%-0.8pp | 0.3%-4.6pp | 0.7%-1.6pp |
| Current Ratio | 1.85+0.2x | 1.550.0x | 1.73+0.1x | 1.85+0.2x | 1.610.0x | 1.57-0.2x | 1.60-0.2x | 1.66-0.2x |
| Debt-to-Equity | 0.76-0.6x | 0.67-0.5x | 0.75-0.4x | 0.82-0.4x | 1.31+0.1x | 1.13+0.2x | 1.16+0.3x | 1.25+0.3x |
| Asset Turnover | 0.140.0x | 0.130.0x | 0.160.0x | 0.130.0x | 0.130.0x | 0.140.0x | 0.170.0x | 0.14-0.1x |
| FCF Margin | -12.7%+6.0pp | 5.7%+0.8pp | 21.2%+5.5pp | -6.3%-7.0pp | -18.7%-15.7pp | 4.9%+4.8pp | 15.7%-4.7pp | 0.7%-1.6pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Bruker Corporation BRKR | FY2025 | $3.4B | -$8.3M | -0.2% | $9.0B | 44/100 |
| Glaukos Corporation GKOS | FY2025 | $507.4M | -$187.7M | -37.0% | $9.8B | 51/100 |
| Integer Holdings Corporation ITGR | FY2025 | $1.9B | $102.8M | 5.5% | $4.3B | 58/100 |
| Bio-Rad Laboratories, Inc. BIO | FY2025 | $2.6B | $759.9M | 29.4% | $9.8B | 52/100 |
| TransMedics Group, Inc. TMDX | FY2025 | $605.5M | $190.3M | 31.4% | $2.7B | 57/100 |
| GLOBUS MEDICAL INC GMED | FY2025 | $2.9B | $537.9M | 18.3% | $10.0B | 77/100 |
Where Bruker Corporation Ranks
Frequently Asked Questions
What is Bruker Corporation's annual revenue?
Bruker Corporation (BRKR) reported $3.4B in total revenue for fiscal year 2025. This represents a 2.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bruker Corporation's revenue growing?
Bruker Corporation (BRKR) revenue grew by 2.1% year-over-year, from $3.4B to $3.4B in fiscal year 2025.
Is Bruker Corporation profitable?
No, Bruker Corporation (BRKR) reported a net income of -$8.3M in fiscal year 2025, with a net profit margin of -0.2%.
What is Bruker Corporation's EBITDA?
Bruker Corporation (BRKR) had EBITDA of $288.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bruker Corporation have?
As of fiscal year 2025, Bruker Corporation (BRKR) had $298.8M in cash and equivalents against $1.9B in long-term debt.
What is Bruker Corporation's gross margin?
Bruker Corporation (BRKR) had a gross margin of 45.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bruker Corporation's operating margin?
Bruker Corporation (BRKR) had an operating margin of 2.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bruker Corporation's net profit margin?
Bruker Corporation (BRKR) had a net profit margin of -0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bruker Corporation's return on equity (ROE)?
Bruker Corporation (BRKR) has a return on equity of -0.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bruker Corporation's free cash flow?
Bruker Corporation (BRKR) generated $43.3M in free cash flow during fiscal year 2025. This represents a -68.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bruker Corporation's operating cash flow?
Bruker Corporation (BRKR) generated $134.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bruker Corporation's total assets?
Bruker Corporation (BRKR) had $6.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bruker Corporation's capital expenditures?
Bruker Corporation (BRKR) invested $90.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bruker Corporation spend on research and development?
Bruker Corporation (BRKR) invested $395.2M in research and development during fiscal year 2025.
What is Bruker Corporation's current ratio?
Bruker Corporation (BRKR) had a current ratio of 1.73 as of fiscal year 2025, which is generally considered healthy.
What is Bruker Corporation's debt-to-equity ratio?
Bruker Corporation (BRKR) had a debt-to-equity ratio of 0.75 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bruker Corporation's return on assets (ROA)?
Bruker Corporation (BRKR) had a return on assets of -0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bruker Corporation's P/E ratio?
Bruker Corporation (BRKR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $9.0B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bruker Corporation's price-to-sales ratio?
Bruker Corporation (BRKR) trades at 2.6x sales, its market capitalization divided by revenue of $3.5B revenue, trailing 12 months to June 30, 2026. The market capitalization is $9.0B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bruker Corporation's Altman Z-Score?
Bruker Corporation (BRKR) has an Altman Z-Score of 2.74, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bruker Corporation's Piotroski F-Score?
Bruker Corporation (BRKR) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bruker Corporation's earnings high quality?
Bruker Corporation (BRKR) reported a net loss of $8.3M while generating $134.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bruker Corporation cover its interest payments?
Bruker Corporation (BRKR) has an interest coverage ratio of 1.13x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bruker Corporation?
Bruker Corporation (BRKR) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.